Sanofi’s Ketek Is New Target Of Congressional Scrutiny Of FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Sen. Grassley requests that senior CDER staff address allegations of inappropriate approval of Sanofi-Aventis’ antibiotic Ketek in May 1 letter.
You may also be interested in...
Grassley Places Hold On Von Eschenbach
The FDA commissioner nominee may have to wait as the senator complains about ignored subpoenas and delayed responses by the agency to committee requests.
Grassley Places Hold On Von Eschenbach
The FDA commissioner nominee may have to wait as the senator complains about ignored subpoenas and delayed responses by the agency to committee requests.
Forest’s Faropenem Is “Not Approvable”; Additional Studies Will Take Two Years
FDA decision reflects the agency's new position on the need for superiority studies to support the approval of antibiotics, Replidyne says.